Screener
Hemab Therapeutics Holdings, Inc. COAG Hmb002 — External Discovery And Other Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Hemab Therapeutics Holdings, Inc. in its filing.
Tagged under the XBRL concept coag:ExternalDiscoveryAndOtherExpense.
The source filing: Hemab Therapeutics Holdings, Inc.’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344533
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development personnel-related (excluding equity-based compensation) | $5,835 | $3,362 | $10,536 | $5,786 |
| External research and development costs - sutacimig | 5,371 | 4,651 | 11,166 | 10,604 |
| External research and development costs - HMB-002 | 3,004 | 1,811 | 6,510 | 6,374 |
| External research and development costs - HMB-003 | 1,887 | 526 | 3,945 | 788 |
| External - discovery related costs and other | 3,258 | 2,309 | 6,094 | 3,028 |
| Personnel-related (excluding equity-based compensation) | 1,054 | 863 | 2,086 | 1,623 |
| External - general and administrative | 3,578 | 1,967 | 5,876 | 3,310 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Hemab Therapeutics Holdings, Inc.'s hmb002 — external discovery and other expense?
- Hemab Therapeutics Holdings, Inc. (COAG) reported hmb002 — external discovery and other expense of $3M in Q2 2026.
- What does hmb002 — external discovery and other expense mean?
- This metric represents the aggregate external research and development costs specifically allocated to the Hmb002 clinical program. It captures expenditures related to third-party clinical trial execution, contract research organizations, and specialized discovery activities necessary to advance this specific therapeutic candidate. Monitoring this expense provides insight into the capital intensity and development progress of the company's pipeline assets.
Ask your AI about Hemab Therapeutics Holdings, Inc.'s hmb002 — external discovery and other expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude